Further analyses from the ARTESIA study and the previous NOAH-AFNET 6 trial are needed to try to identify groups where the benefit may outweigh the risk, researchers say.
Related Keywords
Boston , Massachusetts , United States , Hamburg , Germany , Sweden , Canada , Stockholm , Pennsylvania , Philadelphia , California , German , American , Canadian , Christine Albert , Emma Svennberg , Los Angeles , Jeff Healey , Daiichi Sankyo Europe , Bristol Meyers Squibb , Paulus Kirchhof , Stroke Foundation Of Canada , Sinai Medical Center , Canadian Institutes For Health Research , Mcmaster University , Clinical Trials Network , Novartis , Pfizer Alliance , Vascular Center Hamburg , Karolinska Institute , Prevention Intervention Network , University Of Hamburg , German Center , American Heart Association , Medtronic , Hamilton Health Sciences , University Heart , Boston Scientific , Cardiovascular Research , Population Health Research Institute , Heart Association , Scientific Sessions , New England Journal , Cedars Sinai Medical Center , New Subgroup Analysis , European Heart , Canadian Institutes , Health Research , Bristol Meyers Squibb Pfizer Alliance , Stroke Foundation , Canadian Stroke , Advancing Clinical Trials Network , Population Health Research , Daiichi Sankyo , Atrial Fibrillation , F Atrial Fibrillation , Thromboembolism , Stroke , Erebrovascular Accident , Va Cerebrovascular Accident , Anticoagulation Therapy , Anticoagulant , Anticoagulation , Cv , Ardiovascular , Aspirin , Embolism , Heart , Hemorrhage , Bleeding , Meta Analysis , Ischemic Stroke , Stroke Risk , Arrhythmia , Pulmonary Embolism , Ulmonary Embolism Pe , Pulmonary Embolus , Mbolism Pulmonary , Antiplatelet Age ,
comparemela.com © 2020. All Rights Reserved.